Rhumbline Advisers decreased its position in Collegium Pharmaceutical (NASDAQ:COLL) by 8.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,183 shares of the specialty pharmaceutical company’s stock after selling 2,450 shares during the period. Rhumbline Advisers owned 0.08% of Collegium Pharmaceutical worth $465,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Pura Vida Investments LLC purchased a new stake in shares of Collegium Pharmaceutical in the 3rd quarter valued at approximately $1,229,000. First Manhattan Co. purchased a new stake in shares of Collegium Pharmaceutical in the 4th quarter valued at approximately $8,606,000. Wells Fargo & Company MN grew its stake in shares of Collegium Pharmaceutical by 12.8% in the 3rd quarter. Wells Fargo & Company MN now owns 45,254 shares of the specialty pharmaceutical company’s stock valued at $475,000 after buying an additional 5,136 shares during the period. Teton Advisors Inc. grew its stake in shares of Collegium Pharmaceutical by 18.5% in the 4th quarter. Teton Advisors Inc. now owns 32,000 shares of the specialty pharmaceutical company’s stock valued at $591,000 after buying an additional 5,000 shares during the period. Finally, Chartwell Investment Partners LLC purchased a new stake in shares of Collegium Pharmaceutical in the 4th quarter valued at approximately $3,403,000. 86.39% of the stock is owned by institutional investors and hedge funds.
Several analysts have recently weighed in on the stock. Janney Montgomery Scott set a $26.00 price target on shares of Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Tuesday, February 6th. Zacks Investment Research cut shares of Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. BidaskClub raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Thursday, February 15th. Jefferies Group increased their price target on shares of Collegium Pharmaceutical to $32.00 and gave the company a “buy” rating in a research note on Monday, February 12th. Finally, Piper Jaffray set a $33.00 price objective on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Monday, February 12th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $29.17.
NASDAQ:COLL opened at $24.21 on Friday. Collegium Pharmaceutical has a fifty-two week low of $7.37 and a fifty-two week high of $29.90.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Wednesday, March 7th. The specialty pharmaceutical company reported ($0.54) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.02. The firm had revenue of $10.79 million during the quarter, compared to analysts’ expectations of $9.88 million. Collegium Pharmaceutical had a negative net margin of 262.91% and a negative return on equity of 73.00%. The company’s revenue was up 728.4% compared to the same quarter last year. equities analysts expect that Collegium Pharmaceutical will post -0.76 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Rhumbline Advisers Has $465,000 Stake in Collegium Pharmaceutical (COLL)” was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3334477/rhumbline-advisers-has-465000-stake-in-collegium-pharmaceutical-coll.html.
Collegium Pharmaceutical Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.
Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical (NASDAQ:COLL).
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.